Pulmocide Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference
LONDON – January 10, 2025 – Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company developing inhaled opelconazole for patients suffering […]
Pulmocide Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference Read More »